FXR

FXR; NR1H4

FXR

Related Products

Farnesoid X receptor (FXR) is a ligand-activated transcription factor belonging to the nuclear receptor superfamily. FXR regulates the expression of various genes by binding to DNA either as a monomer or a heterodimer with the common partner for NRs, retinoid x receptor (RXR), to FXR response elements. Two known FXR genes exist, the FXRα and FXRβ.

FXR is mainly expressed in liver and small intestine, where it plays an important role in bile acid, lipid, and glucose metabolism. FXR affects several metabolic pathways through its specific target genes, regulating bile acid (BA) synthesis and homeostasis, glucose and lipid metabolism, also exhibiting a crucial role in intestinal bacterial growth and liver regeneration.

FXR Related Products (68)
Antibodies (3)

By Effects:	Inhibitors (5) Agonists (38) Antagonists (15) Activators (7) Modulators (3)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-109096

Nidufexor	Agonist	99.41%
Nidufexor (LMB763) is an orally-available farnesoid X receptor (FXR) agonist for the research of nonalcoholic steatohepatitis (NASH).

HY-50911

Turofexorate isopropyl	Agonist	99.76%
Turofexorate isopropyl (FXR-450) is a potent, selective, and orally bioavailable FXR agonist with EC₅₀ of 4 nM.

HY-13995A

Sevelamer hydrochloride	Inhibitor	≥98.0%
Sevelamer hydrochloride is an orally active and phosphate binding agent used for research of hyperphosphatemia with chronic kidney disease. Sevelamer hydrochloride consists of polyallylamine that is crosslinked with epichlorohydrin.

HY-109197

Vonafexor	Agonist	99.32%
Vonafexor (EYP001) is an orally active, non-steroidal and selective FXR agonist. Vonafexor shows significant HBsAg reduction when combined with Peg-IFNα. Vonafexor can be used for anti-HBV research.

HY-147296

Omesdafexor	Agonist	99.65%
Omesdafexor is a FXR agonist. Omesdafexor can be used in the research of liver disease or a metabolic inflammation-mediated disease.

HY-103704

LY2562175	Agonist	99.26%
LY2562175 is a potent and selective FXR agonist, with an EC₅₀ of 193 nM.

HY-134988

EDP-305	Agonist
EDP-305 is an orally active, potent and selective farnesoid X receptor (FXR) agonist, with EC₅₀ values of 34 nM (chimeric FXR in CHO cells) and 8 nM (full-length FXR in HEK cells). EDP-305 shows a potent and consistent antifibrotic effect. EDP-305 can be used for primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH) research.

HY-151932

FXR agonist 3	Agonist
FXR agonist 3 is an anti-NASH agent, acting by activating FXR. FXR agonist 3 inhibits COL1A1, TGF-β1, α-SMA and TIMP1 expression with anti-fibrogenic activity. FXR agonist 3 significantly reduces liver steatosis and inflammation, improves liver fibrosis level.

HY-138937

NDB	Antagonist	98.94%
NDB is a selective human FXRα (hFXRα) antagonist that is effective in modulating transcription of FXRα downstream genes. NDB can be used in anti-diabetes research.

HY-100443A

trans-PX20606	Agonist	99.24%
PX20606 trans racemate (PX-102 trans racemate) is a FXR agonist with EC₅₀s of 32 and 34 nM for FXR in FRET and M1H assay, respectively.

HY-133890A

Tauro-α-muricholic acid sodium	Antagonist
Tauro-α-muricholic acid (T-α-MCA) sodium is a FXR (Farnesoid X receptor) antagonist (IC₅₀=28μM). Tauro-α-muricholic acid sodium is also a endogenous metabolite that can be found in cecal.

HY-151481

FXR antagonist 1	Antagonist	98.01%
FXR antagonist 1 (compound F6) is an orally active and selective intestinal FXR antagonist (IC₅₀=2.1 μM). FXR antagonist 1 selectively inhibits intestinal FXR signalling through antagonism of intestinal FXR and feedback activation of hepatic FXR to improve hepatic steatosis, inflammation and fibrosis in NASH (nonalcoholic steatohepatitis) models. FXR antagonist 1 can be used in NASH studies.

HY-101273

BAR502	Agonist	99.53%
BAR502 is a dual FXR and GPBAR1 agonist with IC₅₀ values of 2 μM and 0.4 μM, respectively.

HY-153114

HEC96719	Agonist	98.01%
HEC96719 is a selective and orally active tricyclic farnesoid X receptor (FXR) agonist with EC₅₀ values of 1.37 and 1.55 nM by time-resolved fluorescence energy transfer (TR-FRET) and luciferase reporter assays, respectively. HEC96719 significantly improves non-alcoholic steatohepatitis (NASH) and liver fibrosis with favorable tissue distribution in liver and intestine. HEC96719 can be used for the research of non-alcoholic steatohepatitis.

HY-12222S1

Obeticholic Acid-d₄	Agonist	≥98.0%
Obeticholic Acid-d₄ is the deuterium labeled Obeticholic acid. Obeticholic acid (INT-747) is a potent, selective and orally active FXR agonist with an EC50 of 99 nM. Obeticholic acid has anticholeretic and anti-inflammation effect. Obeticholic acid also induces autophagy[1][2][3].

HY-135399

Tauro-obeticholic acid	Agonist	≥98.0%
Tauro-obeticholic acid is an active metabolite of Obeticholic acid. Obeticholic acid is an orally bioavailable farnesoid-X receptor (FXR) agonist.

HY-135400

Glyco-Obeticholic acid	Agonist	≥98.0%
Glyco-obeticholic acid is an active metabolite of Obeticholic acid. Obeticholic acid is a farnesoid X receptor (FXR) agonist.

HY-76847S2

Chenodeoxycholic acid-¹³C	Activator	≥98.0%
Chenodeoxycholic acid-¹³C is the ¹³C-labeled Chenodeoxycholic Acid. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

HY-100443B

(-)-PX20606 (trans isomer)	Agonist
(-)-PX20606 trans isomer is a FXR agonist with EC₅₀s of 18 and 29 nM for FXR in FRET and M1H assay, respectively.

HY-151481A

β-FXR antagonist 1	Antagonist	99.80%
β-FXR antagonist 1 (C 12), an isomer of FXR antagonist 1 (HY-151481) is a FXR antagonist.

Name
Email *

	Sorry, but the email address you supplied was invalid.

FXR

FXR

FXR Related Products (68)

Antibodies (3)

FXR Related Products (68):